3 Long-term Income Plays: Legal And General Group Plc, GlaxoSmithKline Plc And SSE PLC

Legal & General Group Plc (LON: LGEN), GlaxoSmithKline Plc (LON: GSK) and SSE PLC (LON: SSE) will bring joy to long-term income seekers, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Share price growth can give investors a real buzz in the short-term, but it’s the dividend income that brings the most satisfying long-term rewards. If you can generate 4% or 5% a year and use that to buy more shares in the same company, eventually you will be talking real money.

Up to three-quarters of your long-term returns will come from dividend income. The key phrase here is long-term. Here are three income stocks with staying power.

Legal & General Group

Over the last five years, FTSE-listed insurance giant Legal & General Group (LSE: LGEN) has doubled your money in share price growth alone. The last year has been stickier with the stock down 15%, but that won’t worry long-term income seekers, as L&G currently yields 5.62%. In fact, it works in their favour, because if they re-invest their dividends they’ll pick up more stock at the lower price.

Somebody who invested five years ago, when the stock traded at 116p (against 238p today), is effectively getting a yield of 11.5% on their original investment. FTSE insurers have all been hit by wider stock market uncertainty yet L&G still has plenty in its favour, as a major presence in three fast-growing areas: low-cost tracker funds, UK workplace auto-enrolment schemes and bulk annuities. Earnings per share (EPS) are forecast to rise 7% this year and 8% in 2016, when the yield is expected to hit an even juicier 6.4%.

GlaxoSmithKline

Investment fashions change but one thing seems eternal: pharmaceutical giant GlaxoSmithKline (LON: GSK) is still the FTSE 100 poster boy for dividend income. Yet even dividend heroes can suffer their moments of misfortune, with the Chinese bribery scandal and more importantly, fears of a patent cliff, hitting investor sentiment. Glaxo has been trying to wean itself off its dependence on respiratory treatment Advair/Seretide, with sales down sharply on generic competition. Moves to diversify into vaccines and consumer health, pharmaceutical products and the HIV franchise, are finally bearing fruit.

Four years of negative EPS are expected to turn positive with a vengeance in 2016, rising 14%. Forecast dividend growth looks less spectacular, but the yield is expected to continue hovering around 5.4%, perfect for investors who like to play the long game.

SSE

Some may think I’m rash by including utility company SSE (LSE: SSE) under the heading “long-term income plays”. Its dividend may yield a juicy 5.83% but there has been talk of a cut as cover gets stretched. SSE has been hit by falling energy prices and increased retail market competition, as disgruntled customers switch from the Big Six energy companies to smaller challengers.

Management has committed to raising its dividend by RPI inflation at least, a commitment it stands by even though EPS are expected to fall from 124.1p in the year to March 2015 to 111.79p this year, a drop of almost 10%. It also warned that dividend cover could range from around 1.2 times to around 1.4 times over the next three years, but the yield is still forecast to hit 6% by March 2018, suggesting fears of a cut are overplayed. It still has its believers: JP Morgan is overweight with a target price of 1,550p, only slightly above today’s 1,515p. That confirms my view: forget growth, SSE is all about the income, and the income is good.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Is 2026 the year the Diageo share price bounces back?

Will next year be the start of a turnaround for the Diageo share price? Stephen Wright looks at a key…

Read more »

Investing Articles

Here’s my top FTSE 250 pick for 2026

UK investors looking for under-the-radar opportunities should check out the FTSE 250. And 2026 could be an exciting year for…

Read more »

Yellow number one sitting on blue background
Investing Articles

Here’s my number 1 passive income stock for 2026

Stephen Wright thinks a 5.5% dividend yield from a company with a strong competitive advantage is something passive income investors…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Should I sell my Scottish Mortgage shares in 2026?

After a strong run for Scottish Mortgage shares, our writer wonders if he should offload them to bank profits in…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Down 35%! These 2 blue-chips are 2025’s big losers. But are they the best shares to buy in 2026?

Harvey Jones reckons he's found two of the best shares to buy for the year ahead, but he also acknowledges…

Read more »

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

State Pension worries? 3 investment trusts to target a £2.6m retirement fund

Royston Wild isn't worried about possible State Pension changes. Here he identifies three investment trusts to target a multi-million-pound portfolio.

Read more »

Smiling white woman holding iPhone with Airpods in ear
Dividend Shares

4 dirt-cheap dividend stocks to consider for 2026!

Discover four great dividend stocks that could deliver long-term passive income -- and why our writer Royston Wild thinks they’re…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

These fabulous 5 UK stocks doubled in 2025 – can they do it again next year?

These five UK stocks have more than doubled investors' money as the FTSE 100 surges. Harvey Jones wonders if they…

Read more »